{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:22:56Z","timestamp":1791206576654,"version":"4.1.0"},"reference-count":73,"publisher":"XMLink","issue":"5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC-1610230"],"award-info":[{"award-number":["NCC-1610230"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["synapse.koreamed.org"],"crossmark-restriction":false},"short-container-title":["Investig Clin Urol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4111\/icu.2018.59.5.285","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T04:22:22Z","timestamp":1535948542000},"page":"285","update-policy":"https:\/\/doi.org\/10.4111\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Immune checkpoint inhibitors for urothelial carcinoma"],"prefix":"10.4111","volume":"59","author":[{"given":"Hyung Suk","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Urology, Dongguk University Ilsan Medical Center, Dongguk University College of Medicine, Goyang, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-1093","authenticated-orcid":false,"given":"Ho Kyung","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Urology, Center for Prostate Cancer, Hospital and Biomarker Branch, Research Institute, National Cancer Center, Goyang, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18617","reference":[{"key":"10.4111\/icu.2018.59.5.285_ref1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.4111\/icu.2018.59.5.285_ref2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.4111\/icu.2018.59.5.285_ref3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4143\/crt.2018.143","volume":"50","author":"Jung","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.4111\/icu.2018.59.5.285_ref4","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.6004\/jnccn.2016.0131","volume":"14","author":"Clark","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.4111\/icu.2018.59.5.285_ref5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"Alfred Witjes","year":"2017","journal-title":"Eur Urol"},{"key":"10.4111\/icu.2018.59.5.285_ref6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-170149","volume":"4","author":"Galsky","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.4111\/icu.2018.59.5.285_ref8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.7150\/jca.23162","volume":"9","author":"Niegisch","year":"2018","journal-title":"J Cancer"},{"key":"10.4111\/icu.2018.59.5.285_ref9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fimmu.2018.00385","volume":"9","author":"Lichtenegger","year":"2018","journal-title":"Front Immunol"},{"key":"10.4111\/icu.2018.59.5.285_ref10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1053\/j.seminoncol.2015.02.015","volume":"42","author":"Baksh","year":"2015","journal-title":"Semin Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-017-0552-6","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.4111\/icu.2018.59.5.285_ref13","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3389\/fimmu.2017.01679","volume":"8","author":"Efremova","year":"2017","journal-title":"Front Immunol"},{"key":"10.4111\/icu.2018.59.5.285_ref14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.4111\/icu.2018.59.5.285_ref15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.4111\/icu.2018.59.5.285_ref16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00345-015-1709-y","volume":"34","author":"Kates","year":"2016","journal-title":"World J Urol"},{"issue":"Suppl 1","key":"10.4111\/icu.2018.59.5.285_ref17","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.4111\/icu.2016.57.S1.S98","volume":"57","author":"Kim","year":"2016","journal-title":"Investig Clin Urol"},{"key":"10.4111\/icu.2018.59.5.285_ref18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.6004\/jnccn.2017.7036","volume":"15","author":"Chism","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.4111\/icu.2018.59.5.285_ref19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.juro.2016.02.3005","volume":"197","author":"Donin","year":"2017","journal-title":"J Urol"},{"key":"10.4111\/icu.2018.59.5.285_ref20","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.4111\/icu.2018.59.5.285_ref21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2017.11.023","volume":"73","author":"Perez-Gracia","year":"2018","journal-title":"Eur Urol"},{"key":"10.4111\/icu.2018.59.5.285_ref22","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","volume":"23","author":"Inman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.4111\/icu.2018.59.5.285_ref23","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.4111\/icu.2018.59.5.285_ref24","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.4111\/icu.2018.59.5.285_ref26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref27","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.4111\/icu.2018.59.5.285_ref30","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2017.35.6_suppl.398","volume":"35","author":"Lara","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref32","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.eururo.2017.12.001","volume":"73","author":"Galsky","year":"2018","journal-title":"Eur Urol"},{"key":"10.4111\/icu.2018.59.5.285_ref33","unstructured":"US National Library of Medicine. Study of atezolizumab as monotherapy and in combination with platinum-based chemotherapy in participants with untreated locally advanced or metastatic urothelial carcinoma (IMvigor130) [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02807636"},{"key":"10.4111\/icu.2018.59.5.285_ref34","doi-asserted-by":"crossref","first-page":"TPS4590-TPS","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4590","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref35","doi-asserted-by":"crossref","first-page":"TPS539-TPS","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS539","volume":"36","author":"Galsky","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref36","first-page":"1255","volume":"143","author":"Brown","year":"1993","journal-title":"Am J Pathol"},{"key":"10.4111\/icu.2018.59.5.285_ref37","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1016\/j.juro.2006.07.132","volume":"176","author":"Lamy","year":"2006","journal-title":"J Urol"},{"key":"10.4111\/icu.2018.59.5.285_ref38","unstructured":"US National Library of Medicine. Open-label, randomised, multi-drug, biomarker-directed, phase 1b study in pts w\/muscle invasive bladder cancer (BISCAY) [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02546661"},{"key":"10.4111\/icu.2018.59.5.285_ref39","unstructured":"US National Library of Medicine. A study of ramucirumab plus pembrolizumab in participants with gastric or GEJ adenocarcinoma, NSCLC, transitional cell carcinoma of the urothelium, or biliary tract cancer [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02443324"},{"key":"10.4111\/icu.2018.59.5.285_ref40","unstructured":"US National Library of Medicine. A study of nivolumab by itself or nivolumab combined with ipilimumab in patients with advanced or metastatic solid tumors [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01928394"},{"key":"10.4111\/icu.2018.59.5.285_ref41","doi-asserted-by":"crossref","first-page":"TPS4574-TPS","DOI":"10.1200\/JCO.2015.64.8808","volume":"34","author":"Powles","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref42","unstructured":"US National Library of Medicine. Safety and efficacy of MBG453 as single agent and in combination with PDR001 in patients with advanced malignancies [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02608268"},{"key":"10.4111\/icu.2018.59.5.285_ref43","doi-asserted-by":"crossref","first-page":"mdx440.011-mdx440.011","DOI":"10.1093\/annonc\/mdx440.011","volume":"28","author":"Ascierto","year":"2017","journal-title":"Ann Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref44","doi-asserted-by":"crossref","first-page":"CT027-CT","DOI":"10.1158\/1538-7445.AM2016-CT027","volume":"76","author":"Infante","year":"2016","journal-title":"Cancer Res"},{"key":"10.4111\/icu.2018.59.5.285_ref45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/cco.2018.01.03","volume":"7","author":"Pedersen","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref46","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1158\/0008-5472.CAN-13-3583","volume":"74","author":"Cekic","year":"2014","journal-title":"Cancer Res"},{"issue":"Suppl 6","key":"10.4111\/icu.2018.59.5.285_ref47","first-page":"vi114","volume":"27","author":"McCaffery","year":"2016","journal-title":"Ann Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref48","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2017.35.15_suppl.4503","volume":"35","author":"Smith","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref49","unstructured":"US National Library of Medicine. A study of epacadostat (INCB024360) in combination with durvalumab (MEDI4736) in subjects with selected advanced solid tumors (ECHO-203) [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02318277"},{"key":"10.4111\/icu.2018.59.5.285_ref50","unstructured":"US National Library of Medicine. Phase 1\/1b study to evaluate the safety and tolerability of CPI-444 alone and in combination with atezolizumab in advanced cancers [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02655822"},{"key":"10.4111\/icu.2018.59.5.285_ref51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.4111\/icu.2018.59.5.285_ref52","unstructured":"US National Library of Medicine. A study of atezolizumab versus observation as adjuvant therapy in participants with highrisk muscle-invasive urothelial carcinoma (UC) after surgical resection (IMvigor010) [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02450331"},{"key":"10.4111\/icu.2018.59.5.285_ref53","unstructured":"US National Library of Medicine. An investigational immunotherapy study of nivolumab, compared to placebo, in patients with bladder or upper urinary tract cancer, following surgery to remove the cancer (CheckMate 274) [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02632409"},{"key":"10.4111\/icu.2018.59.5.285_ref54","unstructured":"US National Library of Medicine. Pembrolizumab in treating patients with locally advanced bladder cancer [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03244384"},{"key":"10.4111\/icu.2018.59.5.285_ref55","unstructured":"US National Library of Medicine. Neo-adjuvant bladder urothelial carcinoma combination-immunotherapy (NABUCCO) [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03387761"},{"key":"10.4111\/icu.2018.59.5.285_ref56","unstructured":"US National Library of Medicine. Neoadjuvant nivolumab with and without urelumab in patients with cisplatin-ineligible muscle-invasive urothelial carcinoma of the bladder [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02845323"},{"key":"10.4111\/icu.2018.59.5.285_ref57","unstructured":"US National Library of Medicine. Neoadjuvant pembrolizumab for muscle-invasive urothelial bladder carcinoma [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02736266"},{"key":"10.4111\/icu.2018.59.5.285_ref58","unstructured":"US National Library of Medicine. Neoadjuvant pembrolizumab in combination with gemcitabine therapy in cis-eligible\/ineligible UC subjects [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02365766"},{"key":"10.4111\/icu.2018.59.5.285_ref59","unstructured":"US National Library of Medicine. Preoperative MPDL3280A in transitional cell carcinoma of the bladder (ABACUS) [Internet]. cited 2018 Jun 7. Available from:"},{"key":"10.4111\/icu.2018.59.5.285_ref60","unstructured":"US National Library of Medicine. Pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer (NMIBC) (PemBla) [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03167151"},{"key":"10.4111\/icu.2018.59.5.285_ref61","unstructured":"US National Library of Medicine. Pembrolizumab and BCG solution in treating patients with recurrent non-muscleinvasive bladder cancer [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02808143"},{"key":"10.4111\/icu.2018.59.5.285_ref62","unstructured":"US National Library of Medicine. Study of pembrolizumab (MK-3475) in participants with high risk non-muscle invasive bladder cancer (MK-3475-057\/KEYNOTE-057) [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02625961"},{"key":"10.4111\/icu.2018.59.5.285_ref63","unstructured":"US National Library of Medicine. Atezolizumab in treating patients with recurrent BCG-unresponsive non-muscle invasive bladder cancer [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02844816"},{"key":"10.4111\/icu.2018.59.5.285_ref64","unstructured":"US National Library of Medicine. Safety and pharmacology study of atezolizumab alone and in combination with bacille calmette-gu\u00e9rin (BCG) in high-risk non-muscle-invasive bladder cancer (NMIBC) participants [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02792192"},{"key":"10.4111\/icu.2018.59.5.285_ref65","unstructured":"US National Library of Medicine. Phase 2 durvalumab (Medi4736) for bacillus calmette-gu\u00e9rin (BCG) refactory urothelial carcinoma in situ of the bladder [Internet]. cited 2018 Jun 7. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02901548"},{"key":"10.4111\/icu.2018.59.5.285_ref66","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref67","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-017-0299-1","volume":"5","author":"Aggen","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.4111\/icu.2018.59.5.285_ref68","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2016.68.4696","volume":"34","author":"Drake","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.2018.59.5.285_ref69","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4111\/icu.2018.59.5.285_ref70","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.4111\/icu.2018.59.5.285_ref71","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.4111\/icu.2018.59.5.285_ref72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.4111\/icu.2018.59.5.285_ref73","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.seminoncol.2015.05.011","volume":"42","author":"Gajewski","year":"2015","journal-title":"Semin Oncol"}],"container-title":["Investigative and Clinical Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/synapse.koreamed.org\/pdf\/10.4111\/icu.2018.59.5.285","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/synapse.koreamed.org\/DOIx.php?id=10.4111\/icu.2018.59.5.285","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/icurology.org\/DOIx.php?id=10.4111\/icu.2018.59.5.285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T05:03:45Z","timestamp":1589519025000},"score":1,"resource":{"primary":{"URL":"https:\/\/icurology.org\/DOIx.php?id=10.4111\/icu.2018.59.5.285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4111\/icu.2018.59.5.285","relation":{},"ISSN":["2466-0493","2466-054X"],"issn-type":[{"value":"2466-0493","type":"print"},{"value":"2466-054X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"https:\/\/synapse.koreamed.org\/DOIx.php?id=10.4111\/icu.2018.59.5.285","URL":"https:\/\/synapse.koreamed.org\/DOIx.php?id=10.4111\/icu.2018.59.5.285","name":"synapse","label":"Synapse","group":{"name":"multiple_resolution","label":"Full text available at:"}},{"value":"https:\/\/icurology.org\/DOIx.php?id=10.4111\/icu.2018.59.5.285","URL":"https:\/\/icurology.org\/DOIx.php?id=10.4111\/icu.2018.59.5.285","name":"the_journal","label":"the Journal","group":{"name":"multiple_resolution","label":"Full text available at:"}},{"value":"2018-06-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-31","name":"published_online","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"\u00a9 The Korean Urological Association, 2018","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:\/\/creativecommons.org\/licenses\/by-nc\/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","explanation":{"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}]}}